Candel Therapeutics, Inc. (CADL)
Develops virus-based cancer immunotherapies currently in human clinical trials.
$9.68-0.03%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+53.9%
The outlook
CADL is trading near its 52-week highs with strong upward momentum above its key moving averages. Analysts overwhelmingly favor the stock with a Strong Buy consensus, and the average price target sits roughly 112% above the current price. The data reflects substantial bullish positioning, though investors should note this represents analyst expectations rather than guaranteed outcomes.
What’s behind the score
Analyst consensusStrong Buy — 1.2 avg of 8 analysts
Price trendAbove its 50- & 200-day averages
52-week range76% of the way from its 52-week low to high
Price targetAvg target +112% vs current price
Analyst price target
~12-month · 8 analysts$20.50average target+111.8% vs now
Now $9.68
Low $9.00High $29.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$709.3M
52-wk high
$11.36
52-wk low
$4.35
50-day avg
$9.04
200-day avg
$6.47
Trailing P/E
—